Psoriasis has traditionally been considered a helper T cell, type 1 (TH1)-skewed immunologic response, with its cytokines, interleukin (IL)-12, and interferon γ. However, recent elucidation of the TH17 pathway in psoriasis immunopathogenesis has led to the development of therapeutic efforts targeting the IL-17/TH17 axis.1 One of these agents, secukinumab (Novartis Pharmaceuticals), is an injectable, fully human monoclonal antibody that targets IL-17A. Secukinumab was recently approved by the US Food and Drug Administration for treatment of moderate to severe plaque psoriasis following the establishment of safety and effectiveness in 4 clinical trials.2- 5 The most common adverse effects reported were infection, nasopharyngitis, headaches, pruritus, hypertension, and back pain.
Quach OL, Hsu S. Perianal Dermatophytosis During Secukinumab Therapy for Plaque Psoriasis. JAMA Dermatol. 2016;152(4):486-487. doi:10.1001/jamadermatol.2015.4992